(XERS) – Company Press Releases
-
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
-
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
-
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
-
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
-
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
-
Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab
-
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Xeris Biopharma Updates Its Outlook for 2023
-
Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Xeris Biopharma Reports Third Quarter 2023 Financial Results
-
Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023
-
Xeris Biopharma Announces Private Convertible Note Exchange Transactions
-
Xeris to Participate in the 2023 Cantor Global Healthcare Conference
-
Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
-
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
-
Xeris Biopharma Reports Second Quarter 2023 Financial Results
-
Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023
-
Xeris Ships One Millionth Gvoke® Unit
-
Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism
-
Xeris Biopharma to Participate at the Jefferies Healthcare Conference
-
Xeris Biopharma Reports First Quarter 2023 Financial Results
-
Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023
-
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations
-
Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™
-
Xeris Biopharma Appoints Ricki Fairley to Board of Directors
-
Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance
-
Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023
-
Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023
-
Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®
-
Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference
-
Xeris Biopharma Updates Its Outlook For 2022
-
Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism
-
Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab
-
Xeris Biopharma Reports Third Quarter 2022 Financial Results and Recent Events
-
Xeris Biopharma to Report Third Quarter 2022 Financial Results on November 9, 2022
-
Xeris Biopharma Announces Results of the Extended Evaluation of Recorlev® (Levoketoconazole) From the Phase 3 Sonics Study Published in the European Journal of Endocrinology
-
Xeris Biopharma Announces Positive Topline Phase 1 Clinical Data of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121); Hosts Conference Call and Webcast
-
Xeris Biopharma Reports Second Quarter Financial Results and Upcoming Events
-
Xeris Biopharma to Report Second Quarter 2022 Financial Results on August 10, 2022
-
Xeris’ Commercialization Partner for Ogluo®, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics
-
Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14
-
Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events
-
Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022
-
Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above
-
Xeris Biopharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Events
-
Xeris Announces $150M Senior Secured Term Loan Facility With Hayfin Capital
-
Xeris Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
-
Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
-
Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome
Back to XERS Stock Lookup